Call for BOPA subcommittee members

Dear BOPA members
We are seeking enthusiastic members to join a number of our subcommittees.  Joining a sub-committee is a great opportunity to work with individuals from around the country to progress the oncology pharmacy profession. Time commitment is variable but we estimate a commitment of around 2 hours a month.  All meetings will be via teleconference and any face to face meetings will be optional with travel and accommodation reimbursable.  We are aiming for all our sub-committees to have a technician representative and will also offer a new to oncology “shadowing” position.  This position for new to oncology will be to participate in teleconferences and work with the chairs to learn about the subcommittee, structure and vision; further project participation is optional.  Within BOPA we want to ensure that we are meeting the needs of technician members especially as the roles are variable and evolving.  If you are technician or know a technician that would like to join a subcommittee please get in touch!

Subcommittees in need of members are:

Education and Training
Pharmacist committee members
Technician committee members
New to Oncology

Audit and Research
Technician committee members
New to Oncology

Community Pharmacy
New to Oncology

Digital
Technician committee members
New to Oncology

GAP (Guidelines, Advocacy and Publications)
New to Oncology

If you are interested in joining any of our subcommittees please contact us using the contact us page on the BOPA website here: https://www.bopa.org.uk/contact/  (Subject – other)

Kind Regards

The BOPA Committee

Latest News

By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
By BOPA IO SAG on 23rd April 2025

Toolkit for Immunotherapy IV to SC switch

Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…

Read article
By BOPA E&T subcommittee on 17th April 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…

Read article
By BOPA research subcommittee on 17th April 2025

Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…

Read article